<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment</h2>
    <div class="badge">2025-09-15T17:18:55+00:00</div>
    <ul>
      <li>The current share price of $94.03, remaining just 4.6% below the consensus price target of $98.63, indicates that the market perceives the stock as fairly priced, likely reflecting the anticipated earnings and market pos</li>
<li>Over a longer-term period of three years, Medtronic delivered a total shareholder return of 15.85%, illustrating steady growth.</li>
<li>Concerning the revenue and earnings forecasts, the positive sentiment from Medtronic&#x27;s new product initiatives aligns with analysts&#x27; expectations of annual revenue growth of 5.4% and margins reaching 15.6% over the next</li>
<li>This growth is contextualized by its recent 18.7% increase in earnings over the past year, which exceeded the broader medical equipment industry&#x27;s 12.6% growth.</li>
<li>Despite underperforming the broader US market over the past year, spurred by a 18.5% overall market return, Medtronic&#x27;s focused initiatives and innovations aim to sustain its market relevance.</li>
<li>Medtronic has recently initiated the ELEVATE-HFpEF study focusing on heart failure treatment, which, alongside other product developments and strategic initiatives, coincides with a positive quarter-end price movement of</li>
<li>You should learn about the 1 warning sign we&#x27;ve spotted with Medtronic.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment\n• The current share price of $94.03, remaining just 4.6% below the consensus price target of $98.63, indicates that the market perceives the stock as fairly priced, likely reflecting the anticipated earnings and market pos\n• Over a longer-term period of three years, Medtronic delivered a total shareholder return of 15.85%, illustrating steady growth.\n• Concerning the revenue and earnings forecasts, the positive sentiment from Medtronic&#x27;s new product initiatives aligns with analysts&#x27; expectations of annual revenue growth of 5.4% and margins reaching 15.6% over the next\n• This growth is contextualized by its recent 18.7% increase in earnings over the past year, which exceeded the broader medical equipment industry&#x27;s 12.6% growth.\n• Despite underperforming the broader US market over the past year, spurred by a 18.5% overall market return, Medtronic&#x27;s focused initiatives and innovations aim to sustain its market relevance.\n• Medtronic has recently initiated the ELEVATE-HFpEF study focusing on heart failure treatment, which, alongside other product developments and strategic initiatives, coincides with a positive quarter-end price movement of\n• You should learn about the 1 warning sign we&#x27;ve spotted with Medtronic." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/medtronic-mdt-launches-global-study-171855891.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>